APCCC 2019 PRESENTATION SLIDES

Get Free Access to Session Slides

APCCC 2019 VL

The Definition and Overview of Treatment Options in nmCRPC Presentation - Howard Scher

Details
Howard Scher presents an overview of treatment options for non-metastatic castration-resistant prostate cancer, (nmCRPC), those patients who never had detectable metastases on “conventional/standard” imaging, which includes a radionuclide bone scan and CT abdomen/pelvis +/- and MRI. These patients are generally asymptomatic from cancer itself with some symptoms from prior therapies. Importantly, t...

Local Treatment of the Primary Tumor (Radiotherapy) in the Metastatic Setting - Robert Bristow

Details
In this presentation, Robert Bristow speaks on the concept of local radiotherapy to the primary tumor in the metastatic prostate cancer setting at the Advanced Prostate Cancer Consensus Conference (APCCC) 2019. Dr. Bristow's presentation covers the concept of oligometastatic disease, the rationale for treating the primary tumor, and the future role of metastases-directed therapy including differen...

Testosterone Measurement – Which Test and When? - Martin Gleave

Details
Martin Gleave presents on the topic of testosterone measurement and its various nuances in the context of advanced prostate cancer at the Advanced Prostate Cancer Consensus Conference (APCCC 2019). Testosterone measurement is important as androgens are the drivers of activity of the androgen receptor. Dr. Gleave supports the periodic assessment of testosterone levels to ensure castrate levels, wit...

The Risk of Dose De-intensifying Treatment, Bone Health in Prostate Cancer - Fred Saad

Details
Alicia Morgans and Fred Saad have a discussion on bone health in prostate cancer patients, an issue for men with advanced prostate cancer and an important topic to keep at the forefront of care. Even though men are living longer, bone metastases increases mortality and impair a person's independence. Fred and Alicia tackle approaching this in your patients, specifically in the metastatic castratio...

The Aging Population: Oncogeriatric Assessment and Treatment Considerations Presentation - Joe O'Sullivan

Details
Joe O'Sullivan presented on the aging population and how to properly assess them in the context of prostate cancer at the Advanced Prostate Cancer Consensus Conference (APCCC) 2019. The age at diagnosis of prostate cancer has been increasing over time, while prostate cancer mortality has been decreasing. Aging is associated with increased comorbidities, which may affect the tolerance of therapies...

The Management of Hot Flushes in Advanced Prostate Cancer - Mark Frydenberg

Details
In this presentation, Mark Frydenberg presents the topic of hot flushes caused by androgen deprivation therapy (ADT) at the Advanced Prostate Cancer Consensus Conference (APCCC 2019). Hot flushes are defined as a subjective feeling of warmth in the upper torso, followed by excessive perspiration. Dr. Frydenberg focuses on the various treatment options for hot flushes, including medical treatments...

The Management of Sexuality and Incontinence in Advanced Prostate Cancer Presentation - Inge Van Oort

Details
Inge van Oort presented the topic of managing sexuality and incontinence issues in patients with advanced prostate cancer at the Advanced Prostate Cancer Consensus Conference (APCCC 2019). When assessing sexual symptoms she references the EAU guidelines on sexual activity and the percentage of prostate cancer patients that will receive androgen deprivation therapy (ADT) at some point in the diseas...

A Subgroup Analysis of mCRPC Clinical Trials Presentation - Susan Halabi

Details
In this presentation, Susan Halabi discusses the implications of subgroup analyses in metastatic castration-resistant prostate cancer (mCRPC) trials during the management of CRPC session at the Advanced Prostate Cancer Consensus Conference (APCCC) 2019. The challenge, according to Dr. Halabi, is balancing the dichotomy of the danger of interpreting subgroup analysis with applying overall results o...

First - Line mCRPC After ADT + Docetaxel or AR Pathway Inhibitor Presentation - Mary-Ellen Taplin

Details
Mary-Ellen Taplin presents on the first-line treatment of metastatic castration-resistant prostate cancer (mCRPC) after docetaxel or AR pathway inhibitors in the metastatic hormone-sensitive prostate cancer (mHSPC) setting. There are currently no prospective clinical trial data to guide the optimal selection of treatment for first-line mCRPC after ADT/docetaxel or ADT/AR-inhibition. Dr. Taplin exp...

The Treatment of Non-Metastatic Castration-Resistant Prostate Cancer: "Pros" Presentation - Maha Hussain

Details
Maha Hussain presents during the Management of Castration-Resistant Prostate Cancer (CRPC) debate at the Advanced Prostate Cancer Consensus Conference (APCCC) 2019. Dr. Hussain focuses on the "pros" of treating men with non-metastatic CRPC while revisiting the transformation of the field back to 2011 where stood an area of unmet need. The past 18 months have seen the reporting and FDA approval of...